{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-037974","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.385874+00:00","generated_at":"2026-05-31T08:17:10.144648+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BridgeBio forms GondolaBio JV with $300M investor commitment; retains 45% stake","bullets":["BridgeBio contributed early-stage programs for Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex.","Investors including Viking Global, Patient Square, Sequoia, Frazier, Cormorant, and Aisling committed $300M in tranches.","CEO Neil Kumar's entity also invested; BridgeBio's initial interest ~45%, subject to dilution.","Special committee of independent directors approved with Goldman Sachs as financial advisor.","JV will research, develop, manufacture and commercialize the contributed programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-037974","json":"https://secwatch.observer/filing/0001140361-24-037974.json","markdown":"https://secwatch.observer/filing/0001140361-24-037974.md","text":"https://secwatch.observer/filing/0001140361-24-037974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124037974/0001140361-24-037974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124037974/ef20034419_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:17:10.144648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}